Literature DB >> 17977645

Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer.

Remond J A Fijneman1, Beatriz Carvalho, Cindy Postma, Sandra Mongera, Victor W M van Hinsbergh, Gerrit A Meijer.   

Abstract

Interactions between neoplastic cells and neighboring stromal cells affect tumor morphology and behavior. The present study aimed to identify specific chromosomal aberrations that influence tumor-stroma interactions in colorectal cancer (CRC). Chromosome copy number changes of 23 carcinomas were analyzed by comparative genomic hybridization (array-CGH). Stroma percentage was determined by quantitative measurements of hematoxylin-eosin stained sections. Loss of 1p36 was associated with a decrease, and loss of 9q34 with an increase in CRC stroma percentage. Moreover, gain of 8q24 was associated with increased stroma percentage in CRCs with 20q gain, a major event in colon adenoma-to-carcinoma progression. These data indicate that different cancer genomes have different effects on tumor-stroma interactions, and suggest that determination of specific chromosomal aberrations in CRCs may be used as clinical parameter to predict tumor behavior.

Entities:  

Mesh:

Year:  2007        PMID: 17977645     DOI: 10.1016/j.canlet.2007.09.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

2.  The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients.

Authors:  N P West; M Dattani; P McShane; G Hutchins; J Grabsch; W Mueller; D Treanor; P Quirke; H Grabsch
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

3.  Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Meike de Wit; Cindy Postma; Pien M Delis-van Diemen; Sandra Mongera; Bauke Ylstra; Mark A van de Wiel; Gerrit A Meijer; Remond J A Fijneman
Journal:  Tumour Biol       Date:  2010-01-21

4.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

5.  Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism.

Authors:  Beatriz Carvalho; Anke H Sillars-Hardebol; Cindy Postma; Sandra Mongera; Jochim Terhaar Sive Droste; Askar Obulkasim; Mark van de Wiel; Wim van Criekinge; Bauke Ylstra; Remond J A Fijneman; Gerrit A Meijer
Journal:  Cell Oncol (Dordr)       Date:  2012-01-26       Impact factor: 6.730

6.  Lumican and versican are associated with good outcome in stage II and III colon cancer.

Authors:  Meike de Wit; Eric J Th Belt; Pien M Delis-van Diemen; Beatriz Carvalho; Veerle M H Coupé; Hein B A C Stockmann; Herman Bril; Jeroen A M Beliën; Remond J A Fijneman; Gerrit A Meijer
Journal:  Ann Surg Oncol       Date:  2012-06-19       Impact factor: 5.344

7.  Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

Authors:  Meike de Wit; Beatriz Carvalho; Pien M Delis-van Diemen; Carolien van Alphen; Jeroen A M Beliën; Gerrit A Meijer; Remond J A Fijneman
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

8.  Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.

Authors:  Malgorzata A Komor; Meike de Wit; Jose van den Berg; Sanne R Martens de Kemp; Pien M Delis-van Diemen; Anne S Bolijn; Marianne Tijssen; Tim Schelfhorst; Sander R Piersma; Davide Chiasserini; Joyce Sanders; Christian Rausch; Youri Hoogstrate; Andrew P Stubbs; Mark de Jong; Guido Jenster; Beatriz Carvalho; Gerrit A Meijer; Connie R Jimenez; Remond J A Fijneman
Journal:  Int J Cancer       Date:  2019-08-30       Impact factor: 7.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.